HomeInsightsPE

Glaxosmithkline Pharmaceuticals Ltd PE Ratio

Glaxosmithkline Pharmaceuticals Ltd PE Ratio

stocks purchased

₹ 0.6 Cr

Volume transacted

stocks purchased

2.1 K

stocks traded

Last Updated time: 04 Oct 15:30 PM

Image

Glaxosmithkline Pharmaceuticals Ltd

NSE: GLAXO

PE

60.2

Last updated: 04 Oct 15:30 PM

Key Highlights

  • The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd is 60.2 as of 04 Oct 15:30 PM.
  • The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 49.4 on March 2019 to 55.8 on March 2024 . This represents a CAGR of 2.05% over 6 years. .
  • The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2747 as of 04 Oct 15:30.
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 21.8. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 158.1. The PE Ratio of Textiles industry is 37.6. In 2024.

Historical P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd

No data available

Company Fundamentals for Glaxosmithkline Pharmaceuticals Ltd

No data available

Image

Glaxosmithkline Pharmaceuticals Ltd

NSE: GLAXO

PRICE

2747.9

12.25 (0.45%)

stock direction

Last updated: 04 Oct 15:30

Share price Over Time

1M

1Y

3Y

5Y

Monitoring Glaxosmithkline Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Share Price

Date
leftPriceleft
03 Oct 20242735.65
01 Oct 20242738.45
30 Sep 20242754.8
27 Sep 20242695.5
26 Sep 20242726.5
25 Sep 20242726.05
24 Sep 20242715.45
23 Sep 20242723.95
20 Sep 20242711
19 Sep 20242698.95

SWOT Analysis Of Glaxosmithkline Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Glaxosmithkline Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Glaxosmithkline Pharmaceuticals Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Key Valuation Metric of Glaxosmithkline Pharmaceuticals Ltd

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Glaxosmithkline Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Revenue of Glaxosmithkline Pharmaceuticals Ltd

No data available

* All values are in crore

Historical EBITDA of Glaxosmithkline Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Net Profit of Glaxosmithkline Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd

No data available

* All values are in %

About Glaxosmithkline Pharmaceuticals Ltd

  • GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
  • The Company is headquartered in Mumbai and it has six branch offices, a manufacturing facility at Nashik in Maharashtra, 22 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
  • The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.
  • The Company's portfolio includes General Medicines, Vaccines and Specialty medicines that help prevent and treat disease.
  • Their prescription medicines range across therapeutic areas, such as Anti-Infectives, Dermatology, Gynaecology, Diabetes, Oncology, Cardiovascular Disease and Respiratory Diseases.

Glaxosmithkline Pharmaceuticals Ltd News Hub

News

GSK Pharma Q1 PAT climbs 39% YoY to Rs 182 crore

Revenue from operations grew by 9.89% year on year (YoY) to Rs 811 crore during the quarte...

Read more

03 Aug 202412:25

News

GlaxoSmithKline Pharmaceuticals to convene board meeting

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Compa...

Read more

18 Jul 202410:38

News

Glaxosmithkline Pharmaceuticals announces change in senior management

Glaxosmithkline Pharmaceuticals announced that Dr. Shalini Menon has been appointed as Exe...

Read more

05 Jul 202413:26

News

Glaxosmithkline Pharmaceuticals Ltd leads losers in 'A' group

Som Distilleries & Breweries Ltd, Godfrey Phillips India Ltd, Confidence Petroleum India L...

Read more

03 Jun 202415:00

News

Board of GlaxoSmithKline Pharmaceuticals recommends Final Dividend

GlaxoSmithKline Pharmaceuticals announced that the Board of Directors of the Company at it...

Read more

17 May 202414:03

News

GlaxoSmithKline Pharmaceuticals to conduct AGM

GlaxoSmithKline Pharmaceuticals announced that the 99th Annual General Meeting(AGM) of the...

Read more

17 May 202416:48

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

FAQs for PE of Glaxosmithkline Pharmaceuticals Ltd

What is the current PE Ratio of Glaxosmithkline Pharmaceuticals Ltd?

The Current PE Ratio of Glaxosmithkline Pharmaceuticals Ltd is 60.16 as on 4 Oct 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 4 Oct 2024.

What was the PE Ratio of Glaxosmithkline Pharmaceuticals Ltd last year?

The PE Ratio of Glaxosmithkline Pharmaceuticals Ltd was 36.73 last year, now the PE ratio is 60.16, showing a year-on-year growth of 63.8%.

What does the PE Ratio of Glaxosmithkline Pharmaceuticals Ltd indicate about its stock?

The PE Ratio of Glaxosmithkline Pharmaceuticals Ltd is 60.16. This ratio indicates that investors are willing to pay 60.16 times the earnings per share for each share of Glaxosmithkline Pharmaceuticals Ltd.

What is the PE Ratio Growth of Glaxosmithkline Pharmaceuticals Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Glaxosmithkline Pharmaceuticals Ltd grew by 63.8% whereas, the EPS ratio grew by -5.4.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*